Nguyen Tuan V, Nelson Anne E, Howe Christopher J, Seibel Markus J, Baxter Robert C, Handelsman David J, Kazlauskas Ray, Ho Ken K
Garvan Institute of Medical Research and Department of Endocrinology, Sydney, Australia.
Clin Chem. 2008 Aug;54(8):1268-76. doi: 10.1373/clinchem.2008.105726. Epub 2008 Jun 20.
The utility of insulinlike growth factor (IGF) axis and collagen markers for a growth hormone (GH) doping test in sport depends on their stability and reproducibility. We sought to determine short-term within-subject variability of these markers in a large cohort of healthy individuals.
We measured IGF-I, IGF binding protein 3 (IGFBP-3), acid labile subunit (ALS), and the collagen markers N-terminal propeptide of type I procollagen (PINP), C-terminal telopeptide of type I collagen (ICTP), and N-terminal propeptide of type III procollagen (PIIINP) in serum samples obtained on multiple occasions (median 3 per participant) over a 2- to 3-week period from 1103 elite athletes (699 men, 404 women) ages 22.2 (5.2) years [mean (SD)]. We estimated between-subject and within-subject variances by mixed-effects ANOVA.
Within-subject variance accounted for 32% to 36% and 4% to 13% of the total variance in IGF markers and collagen markers, respectively. The within-subject CV ranged from 11% to 21% for the IGF axis markers and from 13% to 15% for the collagen markers. The index of individuality for the IGF axis markers was 0.66-0.76, and for the collagen markers, 0.26-0.45. For each marker, individuals with initial extreme measured values tended to regress toward the population mean in subsequent repeated measurements. We developed a Bayesian model to estimate the long-term probable value for each marker.
These results indicate that in healthy individuals the within-subject variability was greater for IGF-I than for the collagen markers, and that where a single measurement is available, it is possible to estimate the long-term probable value of each of the markers by applying the Bayesian approach. Such an application can increase the reliability and decrease the cost of detecting GH doping.
胰岛素样生长因子(IGF)轴和胶原蛋白标志物在体育界生长激素(GH)兴奋剂检测中的效用取决于它们的稳定性和可重复性。我们试图在一大群健康个体中确定这些标志物的短期个体内变异性。
我们在2至3周内多次(每位参与者中位数为3次)采集的血清样本中测量了1103名年龄为22.2(5.2)岁[平均(标准差)]的精英运动员(699名男性,404名女性)的IGF-I、IGF结合蛋白3(IGFBP-3)、酸性不稳定亚基(ALS)以及胶原蛋白标志物I型前胶原N端前肽(PINP)、I型胶原C端末肽(ICTP)和III型前胶原N端前肽(PIIINP)。我们通过混合效应方差分析估计个体间和个体内方差。
个体内方差分别占IGF标志物和胶原蛋白标志物总方差的32%至36%和4%至13%。IGF轴标志物的个体内CV范围为11%至21%,胶原蛋白标志物的个体内CV范围为13%至15%。IGF轴标志物的个体性指数为0.66 - 0.76,胶原蛋白标志物的个体性指数为0.26 - 0.45。对于每个标志物,初始测量值处于极端水平的个体在随后的重复测量中往往会向总体均值回归。我们开发了一个贝叶斯模型来估计每个标志物的长期可能值。
这些结果表明,在健康个体中,IGF-I的个体内变异性大于胶原蛋白标志物,并且在只有单次测量值的情况下,通过应用贝叶斯方法可以估计每个标志物的长期可能值。这种应用可以提高检测GH兴奋剂的可靠性并降低成本。